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Abstract 
Background: Chloroquine (CQ) over three days plus primaquine (PQ) for seven days is the treatment of choice of 
infections by Plasmodium vivax in Bolivia, where 95% of the cases of malaria are attributed to this species. The aim of 
this study was to evaluate the therapeutic efficacy of CQ in this setting.
Methods: Patients in the Amazon region of northern Bolivia, were included in the study from May to November 2011 
and the therapeutic efficacy of CQ was evaluated over a 28-day follow-up period. Patients with P. vivax mono-infection 
received 25 mg/Kg body weight of CQ over three days. The concentrations of CQ + desethylchloroquine (DCQ) in blood 
were determined at days 7 and 28 of follow up; at follow-up and on the day of treatment failure was administered PQ.
Results: One hundred patients fulfilled the inclusion criteria, two were lost to follow up and another two were later 
excluded for protocol violation. Of the 96 patients who completed the follow up 10 showed TF; one presented con-
tinued parasitaemia until day 7 of follow up, three on day 21 and six on day 28 of follow up. The geometric mean of 
CQ + DCQ on day 7 was 321.7 ng/ml (range 197–535 ng/ml). In six patients with TF the CQ + DCQ concentrations in 
blood on the day of TF were >100 ng/ml. The rate of resistance was 6.5%.
Conclusion: The present study demonstrates the presence of resistance to CQ in the treatment of malaria by P. vivax 
in the Amazon region of Bolivia. New clinical trials are needed to establish alternative treatments against these para-
sites in this region of South America.
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Background
In South America, 60% [1] of the cases of malaria are due 
to Plasmodium vivax while, in Bolivia, 93% correspond 
to this parasite and the remaining 7% to Plasmodium 
falciparum. In Bolivia, the first-line therapeutic sched-
ule for infections by P. vivax includes 25  mg/Kg body 
weight of chloroquine (CQ) for three days plus 3.5 mg of 
primaquine (PQ) for 7 days. The first is aimed at reduc-
ing the parasitic load in young forms of the parasite and 
eliminating immature gametocytes while the second drug 
is active against the gametocytes and hypnozoites of this 
species [2].
The first description of resistance to CQ in infections 
by P. vivax was in Papua New Guinea in 1989 [3], with 
the highest rates of resistance being reported on the same 
island of New Guinea [4, 5]. In Latin America, the first 
cases of resistance to CQ in infections by P. vivax were 
reported in Guyana in 1996, with three patients main-
taining parasitaemia in the presence of adequate serum 
levels of CQ [6]. Since then cases of therapeutic failure 
(TF) have been described in different areas of the con-
tinent. However, confirmed resistance according to the 
serum levels of CQ and its main metabolite desethylchlo-
roquine (DCQ) has only been reported in Peru with a 
rate of 1.2% [7] and in Brazil with 5.2% [8].
In 2003, an in vivo evaluation of resistance to CQ was 
carried out in the municipality of Riberalta in Bolivia, 
reporting 15% (9/59 cases) of TF over a 28-day period. 
However, none of the cases showed serum levels of the 
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drug [9]. Another evaluation performed in 2007 in the 
same municipality showed TF of 6% (5/81), however CQ 
blood levels on the day of the evaluation were <100 ng/
ml [10]. The present study is part of the routine monitor-
ing of the therapeutic efficacy of anti-malarial drugs in 
Bolivia following the Pan-American Health Organiza-




The study was developed in the department of Beni, in 
the municipality of Riberalta, in the north of the Amazo-
nia of Bolivia where 18% of the diagnoses of malaria and 
21% of the cases of malaria by P. vivax are reported in 
Bolivia [11].
Study design
The screening methods for surveillance of anti-malarial 
drug efficacy (MSADE) of the WHO [12] were followed. 
The sample size was defined as established in MSADE 
determined by the proportion of TF in South America 
and corresponding to no more than 5%, with a con-
fidence interval of 95% and a precision of 5%. Thus, 73 
patients were to be included with a maximum period of 
seven months. The patients were recruited and followed 
by multidisciplinary teams in two health care centers: La 
Unidad health care centre (LU) and the Cesar Moscoso 
health care centre (CM) in the urban area of the Riber-
alta, being equal distance from each other (3,000 m) The 
inclusion criteria were: patients greater than five years 
of age diagnosed with mono-infection with P. vivax, a 
parasite density of asexual forms of 250–100,000 para-
sites/μl of blood, a temperature >37.5°C or in its absence 
a history of a rise in temperature within the last 48  h. 
Microscopic diagnosis was performed according to the 
practical guidelines of diagnosis of the National Malaria 
Control Programme [13], (thick blood film, Giemsa stain-
ing) and parasite density was calculated per microlitre of 
blood by dividing the number of parasites counted multi-
plied by 6,000, divided by leucocytes counted. The results 
were obtained from the average of two experienced 
microscopists. In the case of a difference in parasitic den-
sity greater than 50%, the final result was considered by 
averaging the result of a third microscopist. The presence 
of gametocytes was also determined in this way.
The exclusion criteria were: pregnant women con-
firmed by rapid pregnancy diagnostic tests (detection of 
human chorionic gonadotropin in urine), patients with 
signs and symptoms of severe malaria, a history of allergy 
to anti-malarial drugs, concomitant presence of severe or 
chronic diseases such as tuberculosis or HIV/AIDS and 
a previous history of having received anti-malarial drugs.
The treatment consisted of the use of chloroquine 
phosphate (Lote FCV 002A, Macleods Pharmaceuticals 
Ltd, India) 25  mg/Kg body weight administered orally 
over 3 days: on days 0 and 1 of the study 10 mg/Kg body 
weight were given and on day 2, 5  mg/Kg body weight 
were administered under strict supervision of the inves-
tigative team. Patients vomiting within half an hour after 
the administration of the drug were given another treat-
ment cycle with the same dose and patients with more 
than two episodes of vomiting were excluded from the 
study.
The patients who accepted to participate in the study 
were followed on days 2, 3, 7, 14, 21 and 28 after the 
treatment. The day of diagnosis was denominated day 
0. After the 28  days of follow-up all the patients were 
treated with PQ 0.5  mg/Kg body weight/day adminis-
tered orally during seven days. Patients with TF or those 
in whom mixed malaria was detected were excluded 
from the study. These patients were then administered 
artemisinin-based combination therapy (ACT) used 
in Bolivia for the treatment of P. falciparum, plus PQ 
0.5 mg/Kg over 7 days.
Two milliliters of blood were obtained by venopunc-
ture from all the patients in the study, with or without 
parasitaemia, on days 7 and 28 of the follow up. The con-
centrations of CQ and DCQ in blood were also deter-
mined by high performance liquid chromatography 
(HPLC) according to the standardized technique of the 
Center for Disease Control in Atlanta, USA in patients 
with TF. The samples obtained were kept at 4°C until 
analysis.
The HPLC was performed using the Shimadzu LC-
10ATVP with RF-10 AXL fluorescence detector under 
the following chromatographic conditions: chroma-
tographic column: Agilent Zorbax SIL, silane packing 
(corresponding to L3 according to USP). Detector: fluo-
rescence, emission 380  nm, excitation 320  nm, mobile 
phase A: methanol and diethylamine (100:0.3); mobile 
phase B: n-hexane, t-butyl methyl ether and diethylamine 
(1:1:0.003), flow gradient: 1.0  ml/min; injection volume 
7  µl and column temperature: 30°C. A concentration of 
CQ + DCQ of 70–99 ng/ml was considered effective to 
eliminate all the asexual and sexual forms of P. vivax in 
blood [14] and a CQ + DCQ concentration >100 ng/ml 
in the presence of parasitaemia was considered to dem-
onstrate resistance to CQ [15–17].
Statistical analysis
The Tableau® 7 (Professional edition) software was used 
to analyse the data of frequency and to measure the data 
of CQ + DCQ. The statistical package SPSS® v 20 (Chi-
cago, IL, USA) 14 was used to compare the means and 
medians of the results of CQ  +  DCQ and associated 
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variables, with parametric and non-parametric models 
of analysis of variance. Kaplan-Meier analysis of survival 
and confidence intervals was analysed by the WHO pro-
gramme for study the in vivo therapeutic efficacy [12]. All 
the contrasts of hypothesis were evaluated with an alpha 
risk of 5% and the estimations were made with a confi-
dence interval of 95%.
Ethical aspects
The study was performed following the recommenda-
tions of the National Committee of Bioethics of Bolivia 
and the Ethical Committee of PAHO (PAHOERC). All 
patients provided informed consent to participate in the 
study, and in those under legal age informed consent was 
obtained from their legal guardians.
Results
From May to November 2011, 656 cases of malaria by P. 
vivax were reported out of a total of 5,290 cases evalu-
ated in the urban area of Riberalta. One hundred of 
these patients (51 in CM and 49 in LU) were included 
in the study. Of the total number of cases evaluated 
64% were males and 36% females, with a median age 
of 20 years (range 5–69 years), and 25% of whom were 
under the age of 15 years. Thirty-one percent (n = 31) 
had an axillary temperature >37°C, the geometric 
mean of PD on day 0 was 3,837.43  parasites/µl (range 
252.35–29,987.15 parasites/µl), The geometric mean of 
CQ administered over the three days of treatment was 
1,332.19  mg (range 375–2,250  mg). The mean haemo-
globin values on day 0 in the females was 10 g/dl (range 
7–14 g/dl) and 12 g/dl (range 8–16 g/dl) in males, and 
75% (n  =  75) had anaemia before initiating the treat-
ment (Table 1).
Response to treatment
Of the 100 patients included in the study two were lost 
to follow up and another two were later excluded; one for 
presenting co-infection by P. falciparum and the other 
for violating the protocol. Therefore, a total of 96 patients 
were followed until day 28 after treatment. Of these 96 
patients 59% (n  =  57) eliminated the parasitaemia on 
day 2; 91% (n = 87) on day 3 and 99% (n = 95) on day 7 
of follow up. Parasitaemia or clinical deterioration were 
not observed until the end of follow up in 89.6% (n = 86). 
Treatment failure was observed on days 7, 21 and 28 fol-
low-up, with 1.04% (n = 1) on day 7, 3.1% (n = 3) on day 
21 and 6.3% (n =  6) on day 28. The median age of the 
patients cured was 21 years (range 5–61 years) and that 
of patients with TF was 14 years (range 5–32 years), with 
the differences being statistically significant (P = <0.05). 
With the Kaplan-Meier analysis the cumulative incidence 
of treatment failure was 0.104 (95% CI 0.057–0.185).
Blood concentrations of CQ + DCQ
The geometric mean CQ + DCQ value in blood of all 
the patients followed with and without TF (n = 96) on 
day 7 was 319.46  ng/ml (range 50–743  ng/ml), being 
109.24 ng/ml (range 34–602 ng/ml) on day 28 of follow 
up (n = 92). In the patient with continued presence of 
parasites in blood until day 7 inclusive the CQ + DCQ 
values on day 7 were 535  µg/ml and the patient was 
excluded from the study. In the 10 patients presenting 
TF the geometric mean of CQ +  DCQ was 321.7  ng/
ml (range 197–535 ng/ml) on day 7, being 113.46 ng/ml 
(range 75–223 ng/ml) on the day of TF. In six patients 
the CQ +  DCQ level on the day of TF was above the 
minimum elimination concentration (MEC) (100  ng/
ml) (Table  2; Figure  1). Using Kaplan-Meier survival 
analysis, the cumulative incidence of therapeutic fail-
ure due to resistance was 0.65 (95% CI 0.029–0.139) 
(Table 3).
Discussion
According to the MSADE [12], the presence of parasites 
from day 7 to 28 of follow up at CQ + DCQ blood con-
centrations >100 ng/ml indicates resistance to CQ. Thus, 
in the Amazon region of Bolivia there is evidence of 
resistance to CQ in P. vivax infections.
The concentration of CQ-DCQ in blood on day 7 
in all the patients with TF was above the MEC of the 
drug. In addition, the geometric mean was 321.7  ng/ml 
(range 197–535 ng/ml) demonstrating the CQ presented 
Table 1 Characteristics of  the patients included in  the 
study
a Haemoglobin level <12 g/dl for females and <13 g/dl for males (according to 
WHO criteria).
Characteristics
Total number of patients recruited 100
Age
 Median age (year, range) 20 (5–69)
 Number of patients <15 years of age 25% (n = 25)
Sex
 Female 36% (n = 36)
 Male 64% (n = 64)
History of fever 97% (n = 97)
Axillary temperature >37°C (day 0) 31% (n = 31)
Geometric mean of parasites/μl (day 0) (CI 
95%)
3,837.43 (252.35–29,987.15)
Geometric mean CQ concentration in mg at 
day 3 (CI 95%)
1,332.19 (375-2,250)
Mean haemoglobin value (day 0)
 Female, g/dl; range 10 (7–14)
 Male, g/dl; range 12 (8–16)
 No. (%) with anaemiaa 75 (75%)
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adequate absorption through the intestinal tract [18]. 
In 6 of the 10 patients with TF it was observed that the 
CQ + DCQ levels on the day of TF were >100 ng/ml using 
Kaplan-Meier survival analysis, the cumulative incidence 
of therapeutic failure due to resistance was 0.65 (95% CI 
0.029–0.139).
Table 2 Results on the day of therapeutic failure (TF)
Concentrations of CQ + DCQ on day 7 and on the day of TF.
a CQ + DCQ D7 chloroquine + desethylchloroquine on day 7 of follow up.
b CQ + DCQ TF chloroquine + desethylchloroquine on the day of therapeutic failure.
Center Day TF Age years Weight (Kg) CQ administered mg CQ + DCQ D7a CQ + DCQ TFb
LU 10 7 32 62 1.500 535
CM 02 21 17 72 1.875 351 102
CM 35 21 9 29 750 247 80
LU 07 21 7 21 525 449 83
CM 42 28 5 16 450 263 117
CM 23 28 14 56 1.500 315 183
CM 43 28 19 61 1.575 197 148
LU 12 28 14 57 1.500 431 223
LU 28 28 14 42 1.050 408 86




















Figure 1 Chloroquine + desethylchloroquine (CQ + DCQ) concentrations in blood on day 7 (D7). Follow and on the day of therapeutic failure 
(DTF) in the 10 patients with therapeutic failure.
Table 3 Estimation of  cumulative incidence (risk) of  current parasitaemia after  chloroquine therapy and  malaria by 
P. vivax adjusted for the concentration of chloroquine + desethylchloroquine (CQ + DCQ) in blood on the day of thera-
peutic failure (TF)
Day Number of patients TF/CQ + DCQ >100 ng/dl Censored Failure cumulative incidence
0 96 0 0 0
2 96 0 3 0
3 93 0 0 0
7 93 1 1 0.01
14 91 0 0 0.01
21 91 1 0 0.022
28 90 4 0 0.065
Total 86 6 4 (95% CI 0.029–0.139)
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Ruebsh et al. confirmed resistance to CQ in infections 
by P. vivax with the levels of the drug in blood, describ-
ing resistance in two out of 177 patients in the Amazon 
region of Peru [7]. Santana Filho reported parasitaemia 
above the MEC of the drug in 11 out of 109 patients in 
the Amazon region of Brazil, although DCQ concentra-
tions were not determined [19]. In addition, Marquez 
et  al. described resistance in seven out of 135 patients 
receiving CQ + PQ in the same Amazon region of Brazil 
[8].
According to the recommendations of the WHO, a 
change in the treatment schedule should be considered 
in cases of proven resistance >10% [2]. The rate of resist-
ance to CQ in Latin America is rising [20] and treatment 
alternatives should be investigated to achieve better con-
trol against malaria in this region. At present combined 
treatments with ACT are recommended for infections by 
P. falciparum because of their demonstrated rapid effec-
tiveness in eliminating the parasitic load and achieving 
complete cure of the disease [2]. This is the alternative 
treatment which should be implemented in the treat-
ment of malaria by P. vivax. Several clinical trials have 
demonstrated the efficacy of the ACT in the treatment 
of malaria P. vivax, with dihydroartemisinin-piperaquine 
being the ACT most frequently studied [21]. Taking into 
account the low prevalence of glucose 6 phosphate dehy-
drogenase deficiency in the Amazon region of South 
America [22], the chosen ACT could be combined with 
PQ [23, 24], with the aim of preventing a recurrence 
of parasitaemia due to circulating hypnozoites, how-
ever further studies are still required to use these drugs 
simultaneous.
Conclusions
In conclusion, 6.5% of resistance to CQ was observed in 
infections by P. vivax in the Amazon region of Bolivia. 
Considering the percentage of resistance found and the 
rate of TF with MEC of the drug in blood on the day 
of TF this resistance could be greater. New treatment 
schedules should be evaluated to guarantee the control of 
malaria in this region.
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